The content on this site is intended for healthcare professionals only
Dr Sophie Papa speaks to ecancer about a study examining the association between immunosuppressive and immunostimulatory drugs and COVID-19.
Dr Papa explains the background behind the study, which collated available information from the literature about the use of these drugs in previous coronavirus infections such as, SARS, MERS, as well as emerging data on COVID-19.
She states there is very little evidence at the moment that suggests the use of immunomodulatory drugs is associated with increased risk of harm in coronavirus infections, and could even be beneficial.
Dr Papa emphasises that further research about this novel infection is needed, and emerging data needs to be shared among the medical community - so that doctors can make the best treatment decisions amidst this global pandemic.
Read the study published in ecancermedicalscience here.
Read the news article here.
Other ecancer resources on COVID-19 can be found here.
Innovating cancer care access for low and middle-income countries
Key insights on breast cancer in Cape Verde
Addressing cancer control challenges in Africa
Prostate cancer
Rectal cancer
Cancer in emergencies: What can we do better to protect the most vulnerable?
Multiple myeloma In Rwanda: The need for further research
Synthetic biology and precision medicine in blood and gynaecological cancers
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
